0001636050-21-000046.txt : 20210419 0001636050-21-000046.hdr.sgml : 20210419 20210419165349 ACCESSION NUMBER: 0001636050-21-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210415 FILED AS OF DATE: 20210419 DATE AS OF CHANGE: 20210419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nassif David W. CENTRAL INDEX KEY: 0001636975 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 21835197 MAIL ADDRESS: STREET 1: C/O STEADYMED THERAPEUTICS, INC. STREET 2: 2410 CAMINO RAMON CITY: SAN RAMON STATE: CA ZIP: 94583 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sio Gene Therapies Inc. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853863315 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 877-746-4891 MAIL ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Gene Therapies Ltd. DATE OF NAME CHANGE: 20190516 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 4 1 wf-form4_161886561553902.xml FORM 4 X0306 4 2021-04-15 0 0001636050 Sio Gene Therapies Inc. SIOX 0001636975 Nassif David W. C/O SIO GENE THERAPIES INC. 130 WEST 42ND STREET, 26TH FLOOR NEW YORK NY 10036 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 2.47 2021-04-15 4 A 0 239000 0 A 2031-04-14 Common Stock 239000.0 239000 D The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. /s/ David Nassif 2021-04-19